Browse

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.